sellModerate cluster of 5
Schoch Charles sold $82k of CADL
See Remarks at Candel Therapeutics, Inc.. 9,971 shares at an average of $8.22, traded Jan 8, 2025, filed Jan 10, 2025.
Warning score
44Value
$82k
9,971 shares
Holdings after
52,549
-16% from before
From 52-week low
+130%
low $3.80, close $8.73
From 52-week high
-12%
high $9.96, as of Jan 8, 2025
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price, last year
Rows in this filing
Every transaction in Form 4 0000950170-25-004199, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 8, 2025 | SOpen-market sale Common Stock | -9,971 | $8.22 | $82k | 52,549 | Jan 10, 2025 |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 14Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Barone Francesca Chief Scientific Officer | $282k | 32,146 | |
| 38Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Tak Paul Peter Chief Executive Officer | $230k | 26,172 | |
| 21Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Nichols William Garrett Chief Medical Officer | $397k | 45,316 | |
| 21Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Schoch Charles See Remarks | $44k | 5,000 | |
| 19Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Tyagarajan Seshu Chief Technology Officer | $276k | 31,278 | |
| 45Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Barone Francesca Chief Scientific Officer | $98k | 13,534 | |
| 43Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Nichols William Garrett Chief Medical Officer | $75k | 10,428 | |
| 51Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Tak Paul Peter Chief Executive Officer | $157k | 21,704 | |
| 43Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Schoch Charles See Remarks | $69k | 9,511 | |
| 45Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Tyagarajan Seshu Chief Technology Officer | $103k | 14,322 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.